RPAP1

Summary

RPAP1 (RNA polymerase II associated protein 1, HGNC:24567) is a protein-coding gene on chromosome 15q15.1, encoding RNA polymerase II-associated protein 1 (Q9BWH6). Forms an interface between the RNA polymerase II enzyme and chaperone/scaffolding protein, suggesting that it is required to connect RNA polymerase II to regulators of protein complex formation. It is a common-essential gene (DepMap: required in 99.7% of cancer cell lines).

This protein forms part of the RNA polymerase II (RNAPII) enzyme complex and may recruit RNAPII to chromatin through its interaction with acetylated histones.

Source: NCBI Gene 26015 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 242 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 99.7% of screened cell lines (common-essential)
• MANE Select transcript: NM_015540

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24567
Approved symbol	RPAP1
Name	RNA polymerase II associated protein 1
Location	15q15.1
Locus type	gene with protein product
Status	Approved
Aliases	DKFZP727M111, KIAA1403, MGC858, FLJ12732
Ensembl gene	ENSG00000103932
Ensembl biotype	protein_coding
OMIM	611475
Entrez	26015

Gene structure

Transcript identifiers

Ensembl transcripts: 29 — 22 protein_coding, 5 retained_intron, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000304330, ENST00000561603, ENST00000561631, ENST00000562303, ENST00000563293, ENST00000564934, ENST00000565035, ENST00000565167, ENST00000566863, ENST00000567866, ENST00000568413, ENST00000569829, ENST00000867487, ENST00000867488, ENST00000867489, ENST00000867490, ENST00000867491, ENST00000867492, ENST00000867493, ENST00000867494, ENST00000867495, ENST00000912250, ENST00000912251, ENST00000912252, ENST00000912253, ENST00000912254, ENST00000912255, ENST00000912256, ENST00000970347

RefSeq mRNA: 1 — MANE Select: NM_015540 NM_015540

CCDS: CCDS10079

Canonical transcript exons

ENST00000304330 — 25 exons

Exon	Start	End
ENSE00000676700	41523771	41523972
ENSE00000676711	41527423	41527605
ENSE00000676714	41527860	41528027
ENSE00000676724	41536129	41536218
ENSE00000676726	41536945	41537201
ENSE00000884062	41522765	41522960
ENSE00000931039	41524991	41525148
ENSE00001152542	41534714	41534935
ENSE00001152548	41536501	41536649
ENSE00001206125	41527167	41527301
ENSE00001206176	41526898	41527068
ENSE00002627228	41544219	41544257
ENSE00003487623	41531023	41531202
ENSE00003504096	41520391	41521147
ENSE00003522540	41528235	41528336
ENSE00003527930	41521738	41521880
ENSE00003539757	41523245	41523354
ENSE00003591135	41517798	41517857
ENSE00003607851	41529470	41529568
ENSE00003653294	41529864	41529979
ENSE00003664868	41524096	41524254
ENSE00003671207	41517176	41517691
ENSE00003674625	41522098	41522250
ENSE00003691075	41518006	41518182
ENSE00003788199	41535512	41535632

Expression profiles

Bgee: expression breadth ubiquitous, 194 present calls, max score 89.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.9423 / max 81.2498, expressed in 1741 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
149528	6.9423	1741

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
hindlimb stylopod muscle	UBERON:0004252	89.83	gold quality
gastrocnemius	UBERON:0001388	88.59	gold quality
apex of heart	UBERON:0002098	88.51	gold quality
muscle of leg	UBERON:0001383	88.02	gold quality
ventricular zone	UBERON:0003053	87.39	gold quality
sural nerve	UBERON:0015488	86.34	gold quality
muscle organ	UBERON:0001630	86.30	gold quality
skeletal muscle organ	UBERON:0014892	86.30	gold quality
mucosa of transverse colon	UBERON:0004991	86.25	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.20	gold quality
ganglionic eminence	UBERON:0004023	86.06	gold quality
lower esophagus mucosa	UBERON:0035834	85.49	gold quality
stromal cell of endometrium	CL:0002255	85.05	gold quality
muscle layer of sigmoid colon	UBERON:0035805	84.51	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.46	gold quality
cortical plate	UBERON:0005343	84.39	gold quality
right adrenal gland	UBERON:0001233	84.13	gold quality
lower esophagus	UBERON:0013473	84.11	gold quality
lower esophagus muscularis layer	UBERON:0035833	84.10	gold quality
heart left ventricle	UBERON:0002084	83.99	gold quality
right frontal lobe	UBERON:0002810	83.96	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	83.94	silver quality
prefrontal cortex	UBERON:0000451	83.86	gold quality
right adrenal gland cortex	UBERON:0035827	83.81	gold quality
body of stomach	UBERON:0001161	83.75	gold quality
skin of leg	UBERON:0001511	83.66	gold quality
cardiac ventricle	UBERON:0002082	83.61	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	83.53	gold quality
esophagus	UBERON:0001043	83.20	gold quality
right ovary	UBERON:0002118	83.19	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.08

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT3

miRNA regulators (miRDB)

14 targeting RPAP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-1197	99.70	67.75	1027
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-3154	98.94	66.55	1455
HSA-MIR-887-5P	98.82	65.90	1347
HSA-MIR-1267	98.24	69.05	837
HSA-MIR-4768-3P	98.16	66.02	2330
HSA-MIR-4700-3P	97.74	68.64	1014
HSA-MIR-665	97.60	65.64	1781
HSA-MIR-1287-5P	96.80	65.30	743
HSA-MIR-6828-3P	96.06	67.61	1155

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.7% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 2)

• Data report the purification of RNA polymerase II-associated protein 1 (RPAP1), a 153-kDa polypeptide of unknown function. (PMID:15282305)
• SII is important for preventing cellular death due to oxidative DNA damage, assisting RNAPII to bypass 8-oxoG (PMID:17374514)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	rpap1	ENSDARG00000075072
mus_musculus	Rpap1	ENSMUSG00000034032
rattus_norvegicus	Rpap1	ENSRNOG00000005483
drosophila_melanogaster	CG32104	FBGN0052104

Protein

Protein identifiers

RNA polymerase II-associated protein 1 — Q9BWH6 (reviewed: Q9BWH6)

All UniProt accessions (5): Q9BWH6, H3BPM3, H3BPY8, H3BRE8, H3BTJ6

UniProt curated annotations — full annotation on UniProt →

Function. Forms an interface between the RNA polymerase II enzyme and chaperone/scaffolding protein, suggesting that it is required to connect RNA polymerase II to regulators of protein complex formation. Required for interaction of the RNA polymerase II complex with acetylated histone H3.

Subunit / interactions. Part of an RNA polymerase II complex that contains POLR2A, POLR2B, POLR2C, POLR2D, POLR2E, POLR2F, POLR2G, POLR2H, POLR2I, POLR2J, POLR2K, POLR2L, RPAP1, FCP1 plus the general transcription factors TFIIB and TFIIF.

Subcellular location. Nucleus.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the RPAP1 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9BWH6-1	1	yes
Q9BWH6-2	2
Q9BWH6-3	3

RefSeq proteins (1): NP_056355* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013929	RPAP1_C	Domain
IPR013930	RPAP1_N	Domain
IPR039913	RPAP1/Rba50	Family
IPR057989	TPR_RPAP1/MINIYO-like	Domain

Pfam: PF08620, PF08621, PF25766

UniProt features (22 total): sequence variant 7, region of interest 4, modified residue 3, splice variant 3, compositionally biased region 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BWH6-F1	75.03	0.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 1121, 72, 321

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 85 (showing top): MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_DN, GOCC_RNA_POLYMERASE_COMPLEX, MODULE_207, MILI_PSEUDOPODIA_CHEMOTAXIS_DN, GOCC_TRANSFERASE_COMPLEX_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS, NUYTTEN_EZH2_TARGETS_DN, GOCC_TRANSFERASE_COMPLEX, SCGGAAGY_ELK1_02, GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN, GOMF_TRANSFERASE_ACTIVITY_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS, PASINI_SUZ12_TARGETS_UP, MTF1_Q4, MTOR_UP.N4.V1_UP, CIITA_TARGET_GENES

GO Biological Process (1): transcription by RNA polymerase II (GO:0006366)

GO Molecular Function (4): DNA binding (GO:0003677), nucleotidyltransferase activity (GO:0016779), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (2): DNA-directed RNA polymerase complex (GO:0000428), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	1
nucleic acid binding	1
transferase activity, transferring phosphorus-containing groups	1
binding	1
catalytic activity	1
RNA polymerase complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

646 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RPAP1	GPN1	Q9HCN4	968
RPAP1	RPAP2	Q8IXW5	932
RPAP1	RPAP3	Q9H6T3	930
RPAP1	POLR2J	P52435	865
RPAP1	RUVBL1	P82276	852
RPAP1	INTS3	Q68E01	810
RPAP1	RUVBL2	Q9Y230	802
RPAP1	PFDN6	O15212	776
RPAP1	MED17	Q9NVC6	766
RPAP1	GPN2	Q9H9Y4	724
RPAP1	GPN3	Q9UHW5	691
RPAP1	POLR2C	P19387	558
RPAP1	SAXO2	Q658L1	475
RPAP1	RNF41	Q9H4P4	454
RPAP1	NDUFAF1	Q9Y375	453

IntAct

75 interactions, top by confidence:

A	B	Type	Score
POLR2J	POLR1C	psi-mi:“MI:0914”(association)	0.830
RPAP1	POLR2L	psi-mi:“MI:0915”(physical association)	0.740
POLR2L	RPAP1	psi-mi:“MI:0915”(physical association)	0.740
POLR2C	POLR2D	psi-mi:“MI:0914”(association)	0.730
POLR2J	POLR2D	psi-mi:“MI:0914”(association)	0.730
POLR2L	RCCD1	psi-mi:“MI:0914”(association)	0.640
GPN2	POLR2B	psi-mi:“MI:0914”(association)	0.640
POLR2L	POLR3A	psi-mi:“MI:0914”(association)	0.640
RPAP1		psi-mi:“MI:0915”(physical association)	0.550
C1orf94	USO1	psi-mi:“MI:0914”(association)	0.550
POLR2J	SUPT5H	psi-mi:“MI:0914”(association)	0.530
POLR1C	POLR3A	psi-mi:“MI:0914”(association)	0.530
GPN1	POLR3A	psi-mi:“MI:0914”(association)	0.530
POLR2M	BIN1	psi-mi:“MI:0914”(association)	0.530
GPN2	POLR2C	psi-mi:“MI:0914”(association)	0.530
POLR2J	MED14	psi-mi:“MI:0914”(association)	0.530
POT1	RPAP1	psi-mi:“MI:0915”(physical association)	0.510
RPAP1	TERF2IP	psi-mi:“MI:0915”(physical association)	0.370
POLK	TIA1	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
PB2	ESYT2	psi-mi:“MI:0914”(association)	0.350
PB2	IPO5	psi-mi:“MI:0914”(association)	0.350
HSPA8	PPP6C	psi-mi:“MI:0914”(association)	0.350
C9orf72	CHD2	psi-mi:“MI:0914”(association)	0.350
Prdm16	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (138): RPAP1 (Two-hybrid), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Co-fractionation), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS), RPAP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A8I6ASZ5, A0JN53, A4IG66, D3Z8X7, D3ZND0, G3X992, O00750, O08836, O70576, P0DKR2, Q15021, Q1JQC5, Q1L5Z9, Q1LWH4, Q1LXZ7, Q2YD98, Q3T1I9, Q3TV65, Q3UJU9, Q4R5Q4, Q5EAU9, Q5JTW2, Q5R6Z1, Q5TC12, Q61249, Q66H15, Q6NY52, Q6P5E6, Q6PBQ2, Q6PI26, Q80TE0, Q80V31, Q80XC6, Q8BIW9, Q8BM55, Q8K2Z4, Q8R3L2, Q8VDP4, Q8WVB6, Q92574

Diamond homologs: A0JN53, O43088, Q04418, Q3T1I9, Q80TE0, Q9BWH6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 94 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
FGFR2 mutant receptor activation	6	74.9×	6e-09
Signaling by FGFR2 IIIa TM	6	59.1×	9e-09
Abortive elongation of HIV-1 transcript in the absence of Tat	7	57.0×	6e-09
RNA Polymerase III Chain Elongation	5	52.0×	3e-07
FGFR2 alternative splicing	7	48.5×	6e-09
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	7	46.8×	6e-09
Signaling by FGFR2	7	46.8×	6e-09
RNA Pol II CTD phosphorylation and interaction with CE	7	46.8×	6e-09

Disease & clinical

Clinical variants and AI predictions

ClinVar

242 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	199
Likely benign	13
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4100 predictions. Top by Δscore:

Variant	Effect	Δscore
15:41518005:CTGAG:C	donor_gain	1.0000
15:41518183:C:CC	acceptor_gain	1.0000
15:41521736:A:AC	donor_gain	1.0000
15:41521737:C:CC	donor_gain	1.0000
15:41523350:CTTGG:C	acceptor_gain	1.0000
15:41523351:TTGG:T	acceptor_gain	1.0000
15:41523355:C:CC	acceptor_gain	1.0000
15:41524985:CCTCA:C	donor_loss	1.0000
15:41524986:CTCAC:C	donor_loss	1.0000
15:41524987:TCA:T	donor_loss	1.0000
15:41524990:C:G	donor_loss	1.0000
15:41525144:CTCAA:C	acceptor_gain	1.0000
15:41525146:CAA:C	acceptor_gain	1.0000
15:41525149:C:CC	acceptor_gain	1.0000
15:41527153:C:CA	donor_gain	1.0000
15:41527161:TCTCA:T	donor_loss	1.0000
15:41527162:CTCAC:C	donor_loss	1.0000
15:41527163:TCA:T	donor_loss	1.0000
15:41527164:CACC:C	donor_loss	1.0000
15:41527165:A:AC	donor_gain	1.0000
15:41527165:AC:A	donor_gain	1.0000
15:41527165:ACC:A	donor_gain	1.0000
15:41527165:ACCC:A	donor_loss	1.0000
15:41527166:C:CC	donor_gain	1.0000
15:41527166:C:CG	donor_loss	1.0000
15:41527166:CC:C	donor_gain	1.0000
15:41527166:CCC:C	donor_gain	1.0000
15:41527166:CCCT:C	donor_gain	1.0000
15:41527297:AGCCC:A	acceptor_gain	1.0000
15:41527298:GCCC:G	acceptor_gain	1.0000

AlphaMissense

8871 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:41529552:A:G	F359S	0.997
15:41529551:G:C	F359L	0.994
15:41529551:G:T	F359L	0.994
15:41529553:A:G	F359L	0.994
15:41528302:A:G	L398P	0.991
15:41528292:G:C	S401R	0.990
15:41528292:G:T	S401R	0.990
15:41528294:T:G	S401R	0.990
15:41528311:A:G	L395P	0.986
15:41529552:A:C	F359C	0.986
15:41528329:C:T	G389E	0.985
15:41528327:A:C	Y390D	0.984
15:41525034:A:G	W678R	0.983
15:41525034:A:T	W678R	0.983
15:41528327:A:G	Y390H	0.983
15:41529493:G:C	H379D	0.983
15:41528326:T:G	Y390S	0.982
15:41529495:A:G	L378P	0.982
15:41528266:G:T	A410E	0.981
15:41529908:A:G	W339R	0.981
15:41529908:A:T	W339R	0.981
15:41528277:C:A	Q406H	0.980
15:41528277:C:G	Q406H	0.980
15:41529906:C:A	W339C	0.980
15:41529906:C:G	W339C	0.980
15:41528330:C:A	G389W	0.979
15:41520783:A:G	W1135R	0.978
15:41520783:A:T	W1135R	0.978
15:41528314:T:A	E394V	0.977
15:41528274:T:A	R407S	0.976

dbSNP variants (sampled 300 via entrez): RS1000107201 (15:41533039 A>G), RS1000413624 (15:41533334 G>C), RS1000468839 (15:41520406 G>A,T), RS1000573540 (15:41520367 G>A), RS1000665908 (15:41525977 T>C), RS1000890547 (15:41529266 T>G), RS1000975269 (15:41533197 C>T), RS1001019947 (15:41545622 A>T), RS1001022257 (15:41546138 C>T), RS1001274490 (15:41539773 C>T), RS1001340927 (15:41523029 G>A,C), RS1001669988 (15:41535429 G>T), RS1001696757 (15:41543255 G>C), RS1001941866 (15:41529146 C>T), RS1002144972 (15:41518784 A>G)

Disease associations

OMIM: gene MIM:611475 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST006666_16	Lipid traits (pleiotropy) (HIPO component 1)	4.000000e-09
GCST007430_126	Peak expiratory flow	3.000000e-07
GCST007431_120	Lung function (FEV1/FVC)	4.000000e-23
GCST007923_11	Medication use (drugs used in diabetes)	1.000000e-08
GCST012495_5	Lung function (FEV1/FVC)	2.000000e-13
GCST90020024_479	A body shape index	2.000000e-08
GCST90020025_444	Waist-to-hip ratio adjusted for BMI	4.000000e-11
GCST90020027_622	Waist-hip index	6.000000e-11
GCST90020029_285	Waist circumference adjusted for body mass index	4.000000e-08

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0004574	total cholesterol measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0009718	peak expiratory flow
EFO:0004713	FEV/FVC ratio
EFO:0009924	Drugs used in diabetes use measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067272 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.19	Kd	6.447	nM	CHEMBL5653589
8.19	ED50	6.447	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149238: Binding affinity to human RPAP1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0064	uM

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methacrylaldehyde	affects cotreatment, affects expression, increases expression, increases abundance	2
Acrolein	increases abundance, affects cotreatment, affects expression, increases expression	2
Ozone	increases expression, increases abundance, affects cotreatment, affects expression	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, affects expression, increases abundance	1
sodium arsenite	increases expression	1
aflatoxin B2	decreases methylation	1
coumarin	increases phosphorylation	1
epigallocatechin gallate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
Air Pollutants	affects cotreatment, affects expression, increases abundance	1
Atrazine	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	decreases expression	1
Ivermectin	decreases expression	1
Potassium Dichromate	increases expression	1
Quercetin	increases expression	1
Rotenone	decreases expression	1
Smoke	decreases expression	1
T-2 Toxin	increases expression	1
Testosterone	increases expression	1
Tretinoin	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases methylation	1
Copper Sulfate	decreases expression	1
Volatile Organic Compounds	affects cotreatment, affects expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652280	Binding	Binding affinity to human RPAP1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.